University of California, San Francisco, San Francisco, California.
Johns Hopkins University, School of Medicine, Baltimore, Maryland.
Gastroenterology. 2018 Aug;155(2):422-430.e1. doi: 10.1053/j.gastro.2018.04.009. Epub 2018 Apr 12.
BACKGROUND & AIMS: The American Consortium of Early Liver Transplantation for Alcoholic Hepatitis comprises 12 centers from 8 United Network for Organ Sharing regions studying early liver transplantation (LT) (without mandated period of sobriety) for patients with severe alcoholic hepatitis (AH). We analyzed the outcomes of these patients.
We performed a retrospective study of consecutive patients with a diagnosis of severe AH and no prior diagnosis of liver disease or episodes of AH, who underwent LT before 6 months of abstinence from 2006 through 2017 at 12 centers. We collected data on baseline characteristics, psychosocial profiles, level of alcohol consumption before LT, disease course and treatment, and outcomes of LT. The interval of alcohol abstinence was defined as the time between last drink and the date of LT. The primary outcomes were survival and alcohol use after LT, defined as slip or sustained.
Among 147 patients with AH who received liver transplants, the median duration of abstinence before LT was 55 days; 54% received corticosteroids for AH and the patients had a median Lille score of 0.82 and a median Sodium Model for End-Stage Liver Disease score of 39. Cumulative patient survival percentages after LT were 94% at 1 year (95% confidence interval [CI], 89%-97%) and 84% at 3 years (95% CI, 75%-90%). Following hospital discharge after LT, 72% were abstinent, 18% had slips, and 11% had sustained alcohol use. The cumulative incidence of any alcohol use was 25% at 1 year (95% CI, 18%-34%) and 34% at 3 years (95% CI, 25%-44%) after LT. The cumulative incidence of sustained alcohol use was 10% at 1 year (95% CI, 6%-18%) and 17% at 3 years (95% CI, 10%-27%) after LT. In multivariable analysis, only younger age was associated with alcohol following LT (P = .01). Sustained alcohol use after LT was associated with increased risk of death (hazard ratio, 4.59; P = .01).
In a retrospective analysis of 147 patients who underwent early LT (before 6 months of abstinence) for severe AH, we found that most patients survive for 1 year (94%) and 3 years (84%), similar to patients receiving liver transplants for other indications. Sustained alcohol use after LT was infrequent but associated with increased mortality. Our findings support the selective use of LT as a treatment for severe AH. Prospective studies are needed to optimize selection criteria, management of patients after LT, and long-term outcomes.
美国酒精性肝炎早期肝移植联盟由 8 个美国器官共享联合网络地区的 12 个中心组成,旨在研究严重酒精性肝炎(AH)患者在无戒酒期的情况下进行早期肝移植(LT)的效果。我们分析了这些患者的结局。
我们对 2006 年至 2017 年期间在 12 个中心接受 LT 治疗的无既往肝脏疾病或 AH 发作且确诊为严重 AH 且无戒酒史的连续患者进行回顾性研究。我们收集了基线特征、心理社会特征、LT 前的饮酒量、疾病过程和治疗以及 LT 结局的数据。戒酒间隔时间定义为末次饮酒至 LT 日期之间的时间。主要结局为 LT 后的生存和饮酒情况,定义为复发或持续饮酒。
在 147 例接受 AH 肝移植的患者中,LT 前的平均戒酒时间为 55 天;54%的患者接受了皮质激素治疗 AH,患者的 Lille 评分中位数为 0.82,终末期肝病钠模型评分中位数为 39。LT 后患者的 1 年累积生存率为 94%(95%CI,89%-97%),3 年生存率为 84%(95%CI,75%-90%)。LT 后出院时,72%的患者完全戒酒,18%的患者有复发,11%的患者持续饮酒。LT 后 1 年累积任何饮酒的发生率为 25%(95%CI,18%-34%),3 年时为 34%(95%CI,25%-44%)。LT 后 1 年累积持续饮酒的发生率为 10%(95%CI,6%-18%),3 年时为 17%(95%CI,10%-27%)。多变量分析显示,只有年龄较小与 LT 后饮酒有关(P=0.01)。LT 后持续饮酒与死亡风险增加相关(风险比,4.59;P=0.01)。
在对 147 例因严重 AH 接受早期 LT(戒酒 6 个月内)的患者进行回顾性分析后,我们发现大多数患者在 1 年(94%)和 3 年(84%)时存活,与接受其他适应症 LT 的患者相似。LT 后持续饮酒虽不常见,但与死亡率增加有关。我们的研究结果支持将 LT 作为严重 AH 的一种治疗方法进行选择性应用。需要前瞻性研究来优化选择标准、LT 后患者的管理和长期结局。